PM534, an Optimized Target-Protein Interaction Strategy through the Colchicine Site of Tubulin
Journal of Medicinal Chemistry · 22.02.2024 · 67 (4) · 2619-2630
DOI: 10.1021/acs.jmedchem.3c01775 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 31.01.2024. Verfasst von Daniel Lucena-Agell und 13 weiteren Autor:innen. Beteiligte Einrichtung: Unidad BICS. Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas, Ramiro de Maeztu 9, 28040 Madrid,…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación, European Commission, Fundación Tatiana Pérez de Guzmán el Bueno.
Abstract (Originalsprache)
Targeting microtubules is the most effective wide-spectrum pharmacological strategy in antitumoral chemotherapy, and current research focuses on reducing main drawbacks: neurotoxicity and resistance. PM534 is a novel synthetic compound derived from the Structure-Activity-Relationship study on the natural molecule PM742, isolated from the sponge of the order Lithistida, family Theonellidae, genus Discodermia (du Bocage 1869). PM534 targets the entire colchicine binding domain of tubulin, covering four of the five centers of the pharmacophore model. Its nanomolar affinity and high retention time modulate a strikingly high antitumor activity that efficiently overrides two resistance mechanisms in cells (detoxification pumps and tubulin βIII isotype overexpression). Furthermore, PM534 induces significant inhibition of tumor growth in mouse xenograft models of human non-small cell lung cancer. Our results present PM534, a highly effective new compound in the preclinical evaluation that is currently in its first human Phase I clinical trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Unidad BICS. Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas, Ramiro de Maeztu 9, 28040 Madrid, Spain.
- PharmaMar S.A., Avda de los Reyes 1, Colmenar Viejo, 28770 Madrid, Spain.
- Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain.
ORCID-Profile: María A Oliva, J Fernando Díaz
Förderung
- Ministerio de Ciencia e Innovación
- European Commission
- Fundación Tatiana Pérez de Guzmán el Bueno
- PharmaMar
Zitieren
APA
Lucena-Agell, D., Guillén, M. J., Matesanz, R., Álvarez-Bernad, B., Hortigüela, R., Avilés, P., Martínez-Díez, M., Santamaría-Núñez, G., Contreras, J., Plaza-Menacho, I., Giménez-Abián, J. F., Oliva, M. A., Cuevas, C., & Díaz, J. F. (2024). PM534, an Optimized Target-Protein Interaction Strategy through the Colchicine Site of Tubulin. Journal of Medicinal Chemistry, 67(4), 2619-2630. https://doi.org/10.1021/acs.jmedchem.3c01775
Vancouver
Lucena-Agell D, Guillén MJ, Matesanz R, Álvarez-Bernad B, Hortigüela R, Avilés P, et al. PM534, an Optimized Target-Protein Interaction Strategy through the Colchicine Site of Tubulin. Journal of Medicinal Chemistry. 2024;67(4):2619-2630. doi:10.1021/acs.jmedchem.3c01775
BibTeX
@article{LucenaAgell2024,
author = {Lucena-Agell, Daniel and Guillén, María José and Matesanz, Ruth and Álvarez-Bernad, Beatriz and Hortigüela, Rafael and Avilés, Pablo and Martínez-Díez, Marta and Santamaría-Núñez, Gema and Contreras, Julia and Plaza-Menacho, Iván and Giménez-Abián, Juan F and Oliva, María A and Cuevas, Carmen and Díaz, J Fernando},
title = {PM534, an Optimized Target-Protein Interaction Strategy through the Colchicine Site of Tubulin},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {4},
pages = {2619--2630},
doi = {10.1021/acs.jmedchem.3c01775}
}
EUVIMED